ReviewThe pharmacogenomics journal2019
Precision dosing of warfarin: open questions and strategies.
Review in The pharmacogenomics journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.The pharmacogenomics journal · 2020Trial
- Taste-Masked Microparticles of Sodium Warfarin Prepared by Hot Melt Extrusion and Thermal Postprocessing.Pharmaceutics · 2026Article
- Generative Artificial Intelligence-Empowered Virtual Evolution of Enzyme with the VERnet Model.ACS catalysis · 2026Article
- Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients.Journal of thrombosis and thrombolysis · 2026Article
- Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.Pharmacogenetics and genomics · 2024Article
- Association Between NAD(P)H Quinone Oxidoreductase 1 (NQO1) Gene Methylation/Expression and Bleeding Incidence Among an Iranian Population Undergoing Warfarin Therapy.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial).Clinical and translational science · 2024Article
- Building and analyzing machine learning-based warfarin dose prediction models using scikit-learn.Translational and clinical pharmacology · 2022Article
- Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.International journal of clinical pharmacy · 2022Review
- The Relationship Among Intestinal Bacteria, Vitamin K and Response of Vitamin K Antagonist: A Review of Evidence and Potential Mechanism.Frontiers in medicine · 2022Review
- Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals.Clinical and translational medicine · 2021Article
- Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.American journal of human genetics · 2021Article
- Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warfarin has a very narrow therapeutic window and obvious interindividual variability in its effects, with many factors contributing to the body's response. Algorithms incorporating multiple genetic, environment and clinical factors have been established to select a precision dose for each patient. A number of randomized controlled trials (RCTs) were conducted to explore whether patients could benefit from these algorithms; however, the results were inconsistent. Some questions remain to be resolved. Recently, new genetic and non-genetic factors have been discovered to contribute to variability in optimal warfarin doses. The results of further RCTs have been unveiled, and guidelines for pharmacogenetically guided warfarin dosing have been updated. Based on these most recent advancements, we summarize some open questions in this field and try to propose possible strategies to resolve them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.